A detailed history of Bank Of America Corp transactions in Madrigal Pharmaceuticals, Inc. stock. As of the latest transaction made, Bank Of America Corp holds 239,554 shares of MDGL stock, worth $58.9 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
239,554
Previous 113,114 111.78%
Holding current value
$58.9 Million
Previous $30.2 Million 122.19%
% of portfolio
0.01%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$193.33 - $291.99 $24.4 Million - $36.9 Million
126,440 Added 111.78%
239,554 $67.1 Million
Q1 2024

May 15, 2024

SELL
$171.37 - $283.23 $306,752 - $506,981
-1,790 Reduced 1.56%
113,114 $30.2 Million
Q4 2023

Feb 14, 2024

BUY
$120.4 - $237.13 $9.24 Million - $18.2 Million
76,705 Added 200.8%
114,904 $26.6 Million
Q2 2023

Aug 14, 2023

SELL
$203.88 - $312.0 $3.08 Million - $4.72 Million
-15,123 Reduced 28.36%
38,199 $8.82 Million
Q1 2023

May 12, 2023

SELL
$231.06 - $307.08 $9.12 Million - $12.1 Million
-39,477 Reduced 42.54%
53,322 $12.9 Million
Q4 2022

Feb 10, 2023

BUY
$58.39 - $296.54 $3.06 Million - $15.6 Million
52,439 Added 129.93%
92,799 $26.9 Million
Q3 2022

Nov 14, 2022

BUY
$60.57 - $79.51 $1.82 Million - $2.38 Million
29,992 Added 289.27%
40,360 $2.62 Million
Q2 2022

Aug 12, 2022

SELL
$58.04 - $100.2 $1.97 Million - $3.41 Million
-34,009 Reduced 76.64%
10,368 $742,000
Q1 2022

May 16, 2022

BUY
$55.89 - $101.89 $334,333 - $609,505
5,982 Added 15.58%
44,377 $4.35 Million
Q4 2021

Feb 08, 2022

BUY
$72.34 - $95.09 $2.43 Million - $3.2 Million
33,658 Added 710.53%
38,395 $3.25 Million
Q3 2021

Nov 15, 2021

SELL
$78.35 - $105.02 $13,632 - $18,273
-174 Reduced 3.54%
4,737 $377,000
Q2 2021

Sep 13, 2021

BUY
$97.2 - $137.59 $477,349 - $675,704
4,911 New
4,911 $478,000

Others Institutions Holding MDGL

About MADRIGAL PHARMACEUTICALS, INC.


  • Ticker MDGL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 17,103,400
  • Market Cap $4.21B
  • Description
  • Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III c...
More about MDGL
Track This Portfolio

Track Bank Of America Corp Portfolio

Follow Bank Of America Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of America Corp with notifications on news.